Archive WILEX Ad-hoc- and Press Releases 2008

ENGLISH DEUTSCH

Selected press releases of the former years can be found here.

13 October 2008 PR: WILEX releases 9-month Financial Report 2008: Progress in development projects
17 September 2008 PR: Additional information regarding yesterday’s voting rights announcement
11 August 2008 PR: WILEX starts patient recruitment in Phase II breast cancer trial with its uPA inhibitor MESUPRON®* (WX-671)
24 July 2008 PR: Patient recruitment in Phase II trial with MESUPRON®* (WX-671) in pancreatic cancer patients successfully completed
14 July 2008 PR: WILEX reports successful first half year 2008
03 July 2008 PR: Phase III ARISER study with RENCAREX®*: patient recruitment successfully completed
06 June 2008
 
AH: WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE®* (CA9-SCAN)PR: WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE®* (CA9-SCAN)
19 May 2008

PR: Patient recruitment started in Phase III registration trial with CA9-SCAN
10 April 2008 PR: WILEX reports successful first quarter 2008
20 February 2008

PR: WILEX reports a successful financial year 2007 – positive outlook for 2008
11 February 2008 PR: FDA issues Special Protocol Assessment (SPA) for pivotal Phase III trial with CA9-SCAN
28 January 2008 PR: WILEX receives US FDA approval (IND) for clinical Phase II trial with its uPA inhibitor WX-671 in metastatic breast cancer
25 January 2008 PR: Phase I study with uPA inhibitor WX-UK1 successfully completed
Seite gelesen: 291 | Heute: 3